Payment overview · 2025
General Payments
$940.12
44 reported records · 15 companies
Healthcare provider profile · identity verified
David Antonio Rodriguez, D.O.
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation · WALDORF, MD · NPI 1760525919
Verified facts
What the public records show
CMS Open Payments records show David Antonio Rodriguez, D.O. received $940.12 in general payments during 2025 across 44 reported records.
Boston Scientific Corporation accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ztlido.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $258.03 | 27.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $244.00 | 25.9% | 16 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $111.09 | 11.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.88 | 5.6% | 2 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $48.06 | 5.1% | 2 | 2025 |
| INTERNATIONAL REHABILITATIVE SCIENCES, INC | Unresolved — no canonical attribution shown | $43.14 | 4.6% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $33.91 | 3.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.73 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.09 | 2.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.43 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.24 | 2.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.86 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.52 | 1.6% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $15.14 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $940.12 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $258.03 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.31 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.50 | 9 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $111.09 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $98.50 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $52.88 | 2 | 2025 |
Source payment records
|
|||||
| RS 4i Plus Sequential Stimulator Normalized: rs 4i plus sequential stimulator |
Device | INTERNATIONAL REHABILITATIVE SCIENCES, INC | $43.14 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ZTLido ztlido |
2025 | Ztlido | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 524 | 116 |
| Gabapentin | Gabapentin | 277 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 243 | 52 |
| Pregabalin | Pregabalin | 221 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 190 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 179 | 49 |
| Tramadol Hcl | Tramadol Hcl | 94 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 84 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 20 |
| Methocarbamol | Methocarbamol | 60 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 11 |
| Lidocaine | Lidocaine | 51 | 18 |
| Meloxicam | Meloxicam | 50 | 20 |
| Hydromorphone Hcl | Hydromorphone Hcl | 48 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 39 | 32 |
| Baclofen | Baclofen | 37 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Xtampza Er | Oxycodone Myristate | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | 13 |
| Topiramate | Topiramate | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | 11 |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Ztlido | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $940.12 · 44 records | Boston Scientific Corporation | AUSTEDO XR, BOTOX, Belbuca, Exparel, HORIZANT, KYPHON EXPRESS II KYPHOPAK TRAY, Prospera, QULIPTA, RELISTOR, RS 4i Plus Sequential Stimulator, Senza, TZIELD, UBRELVY, VYEPTI, WaveWriter Alpha Prime 16, ZTLido | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ztlido play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with SCILEX PHARMACEUTICALS INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error